S. DEPARTMENT OF COMMERCE ATENT AND TRADEMARK OFFICE FORM PTO-1449

Sheet <u>1</u> of <u>3</u>

T OF ART EITED BY APPLICANT

ATTY. DOCKET:	17341(AP)	SERIAL NO.: 09/504,538	0.1783
APPLICANT:	DONOVAN, Stephen	TITLE: METHOD FOR TREATING THYROID DISORDERS	Jc927
FILING DATE:	February 15, 2000	GROUP: 1653	

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
200	AA	5,667,808	9/16/97	Johnson et al.	424	501	
820	AB	5,674,205	10/7/97	Pasricha et al.	604	232	
7272	AC	5,980,945	11/9/99	Ruiz	424	484	
82	AD	6,007,843	12/28/99	Drizen et al.	424	884	
200	AE	6,011,011	1/4/00	Hageman	514	12	
Δv	AF	6,022,554	2/8/00	Lee et al.	424	423	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
80	BA	94/21300	9/29/94	WO PCT			(yes/no)

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

Øv.	CA	Ahren, B.; Cholinergic and VIPergic Effects on Thyroid Hormone Secretion in the Mouse; Peptides; 1985; 6:585-589.
16/2	СВ	Amenta, F., et al.; Cholinergic Nerves in the Thyroid Gland; Cell and Tissue Res. (1978); 195:367-370.
	CC	Aoki, K.R.; Preclinical Update on BOTOX® (botulinum Toxin Type A)-Purified Neurotoxin
93		Complex Relative to other Botulinum Neurotoxin Preparations; Eur. J. Neurol; 6(Suppl 4):S3-S10; (1999).
89	CD	Bayliss, et al.; Thyroid Disease The Facts; preface; p. 69-70; Oxford University Press (1998).
80	CE	Boyd, R.S., et al.; The Effect of Botulinum Neurotoxin-B on Insulin Release from a B-Cell Line; Movement Disorders (1995); Vol. 10, No. 3; Item 19; 376.
R)	CF	Boyd, R.S., et al.; The Insulin Secreting B-Cell Line HIT-15 Contains SNAP-25 Which is a Target for Botulinum Neurotoxin-A; Movement Disorders (1995); Vol. 10, No. 3; Item 20; 376.

EXAMINER DATE CONSIDERED OF R 1990
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

S. DEPARTMENT OF COMMERCE /ATENT AND TRADEMARK OFFICE FORM PTO-1449

•				्रे
PAT	JUN	0 5	2000	16 34

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET:	17341(AP)	SERIAL NO.: 09/504,538
APPLICANT:	DONOVAN, Stephen	TITLE: METHOD FOR TREATING THYROID DISORDERS
FILING DATE:	February 15, 2000	GROUP: 1453

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

DV	CG	Brandi, M.L., et al.; Interaction of VIPergic and Cholinergic Receptors in Human Thyroid Cell; Peptides; 1987; 8:893-897.
(Sp	СН	Braverman, L.E. (Editor); Diseases of the Thyroid; Humana Press (1997); p. 157.
Ds.	CI	Cardinali, D.P., et al.; Peripheral Neuroendocrinology of the Cervical Autonomic Nervous System; Brazilian J. Med. Biol. Res. (1994); 27(3):573-599.
	CJ	Fauci, A.S., et al. (Editors); Harrison's Principles of Internal Medicine, 14th Edition (1998); McGraw-Hill. Only editorial pages surlied
D)	CK	Garry, M.G., et al.; Evaluation of the Efficacy of a Bioerodible Bupivacaine Polymer System on Antinociception and Inflammatory Mediator Release; Pain; 82(1):49-55 (1999).
D)	CL	Gonelle-Gispert, C., et al.; SNAP-25A AND -25B Isoforms are Both Expressed in Insulin- Secreting Cells and Can Function in Insulin Secretion; Biochem. J. (1999): 339:159-165.
ws		Huffman, L.J., et al.; Muscarinic Modulation of the Vasodilatory Effects of Vasodilatory Effects of Vasoactive Intestinal Peptide at the Rat Thyroid Gland; Neuroendocrinology (1991);53:69-74.
20	CN	Lakomy, M., et al.; Acetylcholine Esterase Positive Nerves in Swine Thyroid; Z. mikroskanat. Forsch., Leipzig 100 (1986) 1, S. 34-38.
w	СО	Laskawi, R., et al.; Up-to-Date Report of Botulinum Toxin Type A Treatment in Patients with Gustatory Sweating (Frey's Syndrome); Laryngoscope 108 (March 1998); 381-384.
مه	CP	Melander, A., et al.; Presence and Influence of Cholinergic Nerves in the Mouse Thyroid; Endocrinology (1979); 105(1):7-9.
D/		Mercadante, S., et al.; Celiac Plexus Block: A Reappraisal; Regional Anesthesia and Pain Medicine; 23(1):37-48 (Jan-Feb 1998).
as .	CR	Ragona, R.M., et al.; Management of Parotid Sialocele with Botulinum Toxin; Laryngoscope 109 (August 1999); 1344-1346.
200	CS	Schantz, E.J. et al.; Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine; Microbiological Reviews; Mar. 1992; Vol. 56, No. 1; 80-99.

EXAMINER DATE CONSIDERED Oct. 19, 2000
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DEPARTMENT OF COMMERCE TENT AND TRADEMARK OFFICE ORM PTO-1449



Sheet	3	of	3	
		O.	J	

LISTOF ART CITED BY APPLICANT

ATTY. DOCKET:	17341(AP)	RADEMARK	SERIAL	NO.: 09/504,538	
APPLICANT:	DONOVAN, Stephen		TITLE:	METHOD FOR TREATING THYROID DISORDERS	
FILING DATE:	February 15, 2000		GROUP:	1653	

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

25	СТ	Singh, B.R.; Critical Aspects of Bacterial Protein Toxins; Natural Toxins II (1996); Plenum Press, New York; pp. 63-84.
WS	CU	Stern, J.E., et al.; Influence of the Autonomic Nervous System on Calcium Homeostasis in the Rat; Biol Signals (1994); 3:15-25.
	CV	Stevens, P.D., et al.; Managing Chronic Pancreatitis Pain: A Block in Time; AJG; 94(4):872-874 (1999).
Øs	CW	Unger, J., et al.; Mechanism of Cholinergic Inhibition of Dog Thyroid Secretion In Viero; Endocrinology; 1984; 114:1266-1271.
	ر د میراند و دسته	
. *		

EXAMINER	Drivarian	DATE CONSIDERED	OCT 19 TAN
			101.11,000
#CV AMINDD. Initial	if and a second a sec	· · · · · · · · · · · · · · · · · · ·	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.